There was no difference in OS in the group diagnosed with estrogen-dependent cancer (HR = 0.84, 95% CI = 0.60 to 1.18, p = 0.32); there was an OS benefit for patients who became pregnant with previously diagnosed hormone receptor positive cancer (HR = 0.57, 95% CI = 0.36 to 0.90, p = 0.01). Here, NR4A1 is linked to cancer.